RecruitingNCT04075305

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Sponsor

UMC Utrecht

Enrollment

8,000 participants

Start Date

Feb 1, 2019

Study Type

OBSERVATIONAL

Summary

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting data from cancer patients who receive radiation treatment using a special MR-Linac machine — a device that combines an MRI scanner and a radiation therapy machine to deliver more precise treatment. The study tracks outcomes to improve future radiation therapy approaches. **You may be eligible if...** - You are 18 years or older - You are scheduled to receive or have already completed imaging or radiation treatment on an MR-Linac machine - You can provide written informed consent **You may NOT be eligible if...** - You have a contraindication to MRI, such as certain metal implants or electronic devices not compatible with MRI - You are pregnant or possibly pregnant - You have severe claustrophobia that would prevent you from undergoing MRI Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONRadiation therapy

Radiation therapy on the CE marked and FDA approved MR-Linac

Locations(18)

Allegheny Health Network

Pittsburgh, Pennsylvania, United States

Md Anderson Cancer Center

Houston, Texas, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Austin Health - Olivia Newton-John Cancer Wellness and Research Centre

Melbourne, Australia

Insitut Jules Bordet

Brussels, Belgium

Sunnybrook Health Sciences Centre/Odette Cancer Centre

Toronto, Ontario, Canada

University Health Network - Princess Margaret Cancer Center

Toronto, Canada

Odense Universitetshospital

Odense, Funen, Denmark

Universitätsklinikum Tübingen

Tübingen, Germany

Università degli Studi di Brescia

Brescia, Italy

IRCCS Ospedale Sacro Cuore Don Calabria

Negrar, Italy

Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital

Amsterdam, Netherlands

Radiotherapiegroep

Deventer, Netherlands

Radiotherapeutisch Instituut Friesland (RIF)

Leeuwarden, Netherlands

Radboud UMC

Nijmegen, Netherlands

University Medical Center Utrecht

Utrecht, Netherlands

The Royal Marsden and The Institute of Cancer Research National Institute for Health Research Biomedical Research Centre

London, United Kingdom

The Christie National Health Service Foundation Trust

Manchester, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04075305

Related Trials

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

NCT046926751 location

Genomic Services Research Program

NCT025959571 location

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

NCT068073593 locations

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

NCT033661161 location

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT0700515433 locations